Effects of prostate-specific antigen testing on familial prostate cancer risk estimates

Journal of the National Cancer Institute

Volumn 102, Issue 17, 2010, Pages 1336-1343

  Bratt, Ola ^a   Garmo, Hans ^b,c   Adolfsson, Jan ^d   Bill Axelson, Anna ^e,f   Holmberg, Lars ^c   Lambe, Mats ^b,e   Stattin, Pär ^g  

^a LUND UNIVERSITY   (Sweden)

^b Regional Oncologic Centre   (Sweden)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d CLINTEC   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^g UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GENETICS; CANCER PATIENT; CANCER REGISTRY; CANCER RISK; CONTROLLED STUDY; GEOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SOCIOECONOMICS; BLOOD; CANCER STAGING; COHORT ANALYSIS; CONFIDENCE INTERVAL; EARLY DIAGNOSIS; FACTUAL DATABASE; GENETICS; IMMUNOLOGY; INCIDENCE; MIDDLE AGED; OBSERVER VARIATION; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; REGISTER; RISK; RISK ASSESSMENT; RISK FACTOR; SWEDEN;

ADULT; AGED; COHORT STUDIES; CONFIDENCE INTERVALS; DATABASES, FACTUAL; EARLY DETECTION OF CANCER; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; OBSERVER VARIATION; ODDS RATIO; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SOCIOECONOMIC FACTORS; SWEDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 77956603909     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq265     Document Type: Article

References (19)

1. Damber JE, Aus G. Prostate cancer. Lancet. 2008;371(9625):1710-1721.
2. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer\analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343(2):78-85.
3. Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P. Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer. 2003;107(5):797-803.
4. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2009;59(1):27-41.
5. Bratt O, Damber JE, Kärvinge C, et al. [The National Board of Health and Welfare's guidelines for prostatic cancer care. PSA test screening\only for well-informed men]. Läkartidningen. 2008;105(8):524-528.
6. Adolfsson J, Garmo H, Varenhorst E, et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol. 2007;41(6):456-477.
7. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
8. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specifc antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374-383.
9. Bratt O, Damber JE, Emanuelsson M, et al. Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancer. Eur J Cancer. 2000;36(2): 235-241.
10. Bermejo JL, Hemminki K. Familial risk of cancer shortly after diagnosis of the frst familial tumor. J Natl Cancer Inst. 2005;97(21):1575-1579.
11. Hemminki K, Rawal R, Bermejo JL. Prostate cancer screening, changing age-specifc incidence trends and implications on familial risk. Int J Cancer. 2005;113(2):312-315.
12. Hagel E, Garmo H, Bill-Axelson A, et al. PCBaSe Sweden: a register-based resource for prostate cancer research. Scand J Urol Nephrol. 2009;43(5):432-439.
13. Barlow L, Westergren K, Holmberg L, Talback M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48(1):27-33.
14. Lagerlund M, Bellocco R, Karlsson P, Tejler G, Lambe M. Socio-economic factors and breast cancer survival\a population-based cohort study (Sweden). Cancer Causes Control. 2005;16(4):419-430.
15. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med. 2008;359(20):2143-2153.
16. Dall'era MA, Hosang N, Konety B, Cowan JE, Carroll PR. Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of signifcant and insignifcant disease. J Urol. 2009; 181(4):1622-1627.
17. Tewari AK, Gold HT, Demers RY, et al. Effect of socioeconomic factors on long-term mortality in men with clinically localized prostate cancer. Urology. 2009;73(3):624-630.
18. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360(13):1320-1328.
19. Leu M, Reilly M, Czene K. Evaluation of bias in familial risk estimates: a study of common cancers using Swedish population-based registers. J Natl Cancer Inst. 2008;100(18):1318-1325.